Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2008 Mar;6(3):364-6. doi: 10.1016/j.cgh.2007.12.020.

Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis.

Author information

1
Miles and Shirley Fiterman Center for Digestive Diseases, Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55906, USA. topazian.mark@mayo.edu

Abstract

BACKGROUND & AIMS:

Biliary strictures occur in a third of patients with autoimmune pancreatitis and have been termed immunoglobulin G subclass 4 (IgG4) associated cholangitis (IAC). IAC often responds to steroid therapy.

METHODS:

A patient with autoimmune pancreatitis and (IAC) refractory to steroids and 6-mercaptopurine was treated with rituximab, a monoclonal antibody directed against the CD20 antigen on B lymphocytes.

RESULTS:

The patient's biliary strictures improved after rituximab therapy, permitting removal of his biliary stents. Systemic manifestations of IgG4-associated disease also improved.

CONCLUSIONS:

Rituximab may be a treatment option for patients with refractory or recurrent autoimmune pancreatitis or IAC.

PMID:
18328441
DOI:
10.1016/j.cgh.2007.12.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center